News
Piper Sandler analyst Edward A. Tenthoff assumed coverage of CytomX Therapeutics (CTMX) with an Overweight rating with a price target of $2.50, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback